TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02856503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Weekly oral dose of Vitamin D3 per protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Weekly oral dose of Vitamin D3 per protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Weekly oral dose of Vitamin D3 per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Weekly oral dose of Vitamin D3 per protocol.
Study: NCT04430114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: branched prosthesis for surgical treatment of thoraco-abdominal aortic aneurysms
Description: Jotec TAAA spinal loop graft custom made CE equivalent branched prosthesis, compared with the cohort of patients already treated with standard prostheses and / or Gelweave ™ Coselli Thoracoabdominal Grafts.
Study: NCT01654731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03762824

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine
Description: Pneumococcal conjugate vaccination during antirheumatic treatment

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine
Description: Pneumococcal conjugate vaccination during antirheumatic treatment

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine
Description: Pneumococcal conjugate vaccination during antirheumatic treatment

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: Pneumococcal polysaccharide vaccination during antirheumatic treatment

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: Pneumococcal polysaccharide vaccination during antirheumatic treatment

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: Pneumococcal polysaccharide vaccination during antirheumatic treatment

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: Pneumococcal polysaccharide vaccination during antirheumatic treatment
Study: NCT00556712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150mg po daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po daily
Study: NCT02703584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buseralin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregnyl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pregnyl
Study: NCT02234960

Intervention type: DRUG
Intervention: Tocilizumab
Description: Tocilizumab will be given according to summary of product characteristics as per clinical practice.
Study: NCT00636142

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: 5 mg/kg body weight, maximal dose 500 mg; intravenous administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Infliximab
Description: 5 mg/kg body weight, maximal dose 500 mg; intravenous administration
Study: NCT02319161

Intervention type: DRUG
Intervention: Calcium channel blocker and beta blocker
Description: The patients in which systolic blood pressure increased to 150 mmHg and above following tourniquet inflation and in which a bolus dose of calcium channel blocker 10 mg (Diltizem, Mustafa Nevzat İlaç Sanayi Aş) (Group I) or beta blocker 0.5mg/kg (Brevibloc, Eczacıbaşı İlaç Sanayi Aş) (Group II) were administered intravenously constituted the study groups.

Intervention type: DRUG
Intervention: Calcium channel blocker and beta blocker
Description: The patients in which systolic blood pressure increased to 150 mmHg and above following tourniquet inflation and in which a bolus dose of calcium channel blocker 10 mg (Diltizem, Mustafa Nevzat İlaç Sanayi Aş) (Group I) or beta blocker 0.5mg/kg (Brevibloc, Eczacıbaşı İlaç Sanayi Aş) (Group II) were administered intravenously constituted the study groups.
Study: NCT04431310

Intervention type: OTHER
Intervention: Serial seroconversion measurements in hospital employees during the COVID-19 pandemic
Description: The aim of this study is to apply serology testing methods for SARS-CoV2 antibodies in samples collected from HCWs in an acute hospital.
Study: NCT02193035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microparticle levels
Description: Microparticle levels will be evaluated with flow cytometry and nanoparticle tracking analysis
Study: NCT02435407

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOS
Description: Ten (10) children will be randomized to participate in the SOS intervention arm. The intervention will be divided into two groups of 5 children with 2 therapists assigned. The children will attend 1 hour intervention sessions once a week for 12 weeks. Here they will be introduced to different types of foods that they would not have typically eaten in a play based group session. The SOS intervention utilizes the principle of hierarchal desensitization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Parents will be given three 1 hour educational talks around the aetiology and management of feeding difficulties in children with autism spectrum disorder. This will be administered at 3 distinct time points; baseline, week 6 and week 12 of the study.
Study: NCT00460759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine
Study: NCT02826421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UltraSert Preloaded Delivery System
Description: Includes AcrySof IQ monofocal posterior chamber IOL Model AU00T0, intended for long term use over the lifetime of the subject

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTec Preloaded Delivery System
Description: Includes TECNIS 1-piece monofocal IOL, intended for long term use over the lifetime of the subject

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iSert Preloaded Delivery System
Description: Includes Model 251 or Model 250 posterior chamber IOL, as selected by the Investigator, intended for long term use over the lifetime of the subject

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monarch III D Manual IOL Delivery System
Description: Includes AcrySof IQ monofocal IOL posterior chamber IOL Model SN60WF, intended for long term use over the lifetime of the subject
Study: NCT04025502

Intervention type: DEVICE
Intervention: Event-Related Potentials (ERP) and Electroencephalogram (EEG) testing with the COGNISION® System
Description: The testing protocol consists of an auditory oddball Event-Related Potential (ERP) paradigm, 40Hz ASSR, and the collection of 6 minutes of resting electroencephalogram (EEG). During the ERP paradigm a variety of auditory stimuli are played through the system's earphones while voltage potentials are recorded from the subject's scalp. At the end of the ERP session, 6 minutes of EEG data will be recorded while the subject is resting. The entire procedure, including set up, instructions to the subject and actual test is expected to take 60-75 minutes.

Intervention type: DEVICE
Intervention: Event-Related Potentials (ERP) and Electroencephalogram (EEG) testing with the COGNISION® System
Description: The testing protocol consists of an auditory oddball Event-Related Potential (ERP) paradigm, 40Hz ASSR, and the collection of 6 minutes of resting electroencephalogram (EEG). During the ERP paradigm a variety of auditory stimuli are played through the system's earphones while voltage potentials are recorded from the subject's scalp. At the end of the ERP session, 6 minutes of EEG data will be recorded while the subject is resting. The entire procedure, including set up, instructions to the subject and actual test is expected to take 60-75 minutes.
Study: NCT02185014

Intervention type: DRUG
Group type: OTHER
Intervention: Adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection
Study: NCT04290793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: 400mg administered as continuous oral once daily from the first day of the study
Study: NCT02792855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: snifﬁng Position(place a 7-cm cushion under head )
Description: Awake fiberoptic bronchoscope(FOB) orotracheal under snifﬁng position.The snifﬁng position was obtained by placement of a 7-cm cushion under the head of the patient. When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simple Head Extension(without cushion)
Description: Awake fiberoptic bronchoscope(FOB) orotracheal under Head Extension position.The Head Extension position was obtained by simple head extension.When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
Study: NCT01535898

Intervention type: OTHER
Intervention: MRI scanner with sequence
Description: The intervention for the patients is the additional 10 minutes in the MRI scanner with sequence. The intervention for the volunteers is the scan, which will take a total of 30 minutes. The volunteers will have two more additional studies at 1-2 week intervals. Both the patients and volunteers will also need to fill out a questionnaire.
Study: NCT04865718

Intervention type: DIAGNOSTIC_TEST
Intervention: ICGA imaging
Description: subjects undergoing intraoperative ICGA imaging
Study: NCT03624283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betahistine
Description: Betahistine is used in the treatment of and vertigo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betahistine
Description: Betahistine is used in the treatment of and vertigo.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise-based vestibular rehabilitation
Description: Exercise-based vestibular rehabilitation (VR) has proven to be an effective way for managing dizziness by relieving symptoms and improving balance and postural stability.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise-based vestibular rehabilitation
Description: Exercise-based vestibular rehabilitation (VR) has proven to be an effective way for managing dizziness by relieving symptoms and improving balance and postural stability.
Study: NCT03884842

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab/Dupixent
Description: a monoclonal antibody designed for the treatment asthma and atopic dermatitis.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT00057499

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBC-VS01
Description: IBC-VS01

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IBC-VS01 placebo
Description: IBC-VS01 placebo
Study: NCT02268708

Intervention type: PROCEDURE
Intervention: Oncological pulmonary resection
Description: Respiratory evaluation before sugery Oncological pulmonary resection with general anesthesia. Hospitalization for post operative care
Study: NCT02798900

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional task-training
Description: The functional task-training program includes warming up followed by a functional circuit with muscle strengthening exercises for the major groups of hip oriented to daily life activities and ends with stretching.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional task-training
Description: The functional task-training program includes warming up followed by a functional circuit with muscle strengthening exercises for the major groups of hip oriented to daily life activities and ends with stretching.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Ultrasound
Description: Therapeutic pulsed ultrasound will be applied prior to functional task-training with an intensity of 2.2 W/cm2, frequency of 1 MHz and application time of 4 minutes on the anterior, medial and lateral hip area.
Study: NCT01808352

Intervention type: DRUG
Group type: OTHER
Intervention: FTC/TDF
Description: All participants will be offered once daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) combined with C4.
Study: NCT00278135

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA (nutritional supplement) or placebo
Description: oral 900mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: DHA (nutritional supplement) or placebo
Description: oral 900mg/day
Study: NCT04233905

Intervention type: BEHAVIORAL
Intervention: Psychometric questionnaire study
Description: Four groups participate in the psychometric questionnaire study. A group of mute children and their mothers (EG:A), as well as a normal, healthy control group (KG:A) with roughly the same age and sex characteristics fill out one-time questionnaires about current daily life experiences. In addition, another group of formerly mute adults (EG:B) as well as a comparable age/sex normal control group will be retrospectively questioned using the same specifically tailored questionnaire.

Intervention type: BEHAVIORAL
Intervention: Psychometric questionnaire study
Description: Four groups participate in the psychometric questionnaire study. A group of mute children and their mothers (EG:A), as well as a normal, healthy control group (KG:A) with roughly the same age and sex characteristics fill out one-time questionnaires about current daily life experiences. In addition, another group of formerly mute adults (EG:B) as well as a comparable age/sex normal control group will be retrospectively questioned using the same specifically tailored questionnaire.

Intervention type: BEHAVIORAL
Intervention: Psychometric questionnaire study
Description: Four groups participate in the psychometric questionnaire study. A group of mute children and their mothers (EG:A), as well as a normal, healthy control group (KG:A) with roughly the same age and sex characteristics fill out one-time questionnaires about current daily life experiences. In addition, another group of formerly mute adults (EG:B) as well as a comparable age/sex normal control group will be retrospectively questioned using the same specifically tailored questionnaire.

Intervention type: BEHAVIORAL
Intervention: Psychometric questionnaire study
Description: Four groups participate in the psychometric questionnaire study. A group of mute children and their mothers (EG:A), as well as a normal, healthy control group (KG:A) with roughly the same age and sex characteristics fill out one-time questionnaires about current daily life experiences. In addition, another group of formerly mute adults (EG:B) as well as a comparable age/sex normal control group will be retrospectively questioned using the same specifically tailored questionnaire.
Study: NCT00918333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT03135782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Skills Training
Description: Undergo motivational interviewing training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Undergo medical chart review

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Attend phone or in-person motivational interviewing coaching sessions
Study: NCT00797056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF 5 mcg/kg/day SQ daily for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline SQ daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 75 mg/day for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Aspirin 75 mg/day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75mg/day daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75mg/day daily for 14 days
Study: NCT05329519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening music
Description: Patients in both groups underwent VATS with wedge recession and the same surgical methods were employed. After the surgery, the patients in the music group performed deep breathing and coughing exercises while listening to music for thirty minutes a day with a MP3 player (Goldmaster Goldsmart Mp3-159 Player) and head phones on postoperative days 1, 2, and 3. We prepared a list of popular songs of different genres, including Turkish classical, folk, pop and rock music, classical music and foreign music, and allowed them to choose the song to be listened.
Study: NCT03267537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine CBT-I
Description: Will be administered in a manner similar to the conventional CBT-I arm except that the patient would not be required to make office visits

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional office-based CBT-I
Description: Conventional office-based CBT-I
Study: NCT03620955

Intervention type: OTHER
Intervention: Justified risk stratification based on MRD after three course chemo therapy
Description: All patients are routinely divided into different risk groups according to the NCCN guild based on cytogenetic and molecular abnormality. Then all patients are treated with anthracycline combined with cytarabine regimens for two courses . The patients without obtaining CR will go on one cycle of salvage therapy and then be bridged to allo-HSCT. Those acquiring CR will be given one more course of HDAC as consolidation treatment and then be detested MRD with flow cytometry after that. The patients with MRD positive would be moved to a higher risk class.The stratified therapy should be considered according to the new risk stratification.
Study: NCT00273052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol Phosphate modified release formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol succinate
Study: NCT01267643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: Dose Escalation Schedule~Level -1 5 mg IV once weekly~Level 1 7.5 mg IV once weekly~Level 2 10 mg IV once weekly~Level 3 12.5 mg IV once weekly
Study: NCT03941106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated repetitive transcranial magnetic stimulation
Description: Subjects will be given accelerated left sided rTMS and randomized to more of the same accelerated rTMS if not meeting remission criteria for depression or a different type of rTMS on the right side

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated repetitive transcranial magnetic stimulation
Description: Subjects will be given accelerated left sided rTMS and randomized to more of the same accelerated rTMS if not meeting remission criteria for depression or a different type of rTMS on the right side
Study: NCT05038215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: adherence promotion techniques
Description: The experimental group will receive adherence promotion techniques in addition to routine care, including 1-additional information tailored for the spouse/partner, persons living with the patient. 2- Educational material delivered at follow up appointments and by mail at intervals agreed upon by the patient and the clinician. 3- Electronic reminder/communication system established by patient and provider. 4-Follow up communication from the dental provider of the oral appliance to the primary care physician and with patient's approval, their general dentist. 5- After the 3 month follow up visits the patient will be provided with reports about their appliance wear per week. 6-Gift card delivery, $25, at 6 month follow up if a follow up with sleep physician is scheduled.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: The control group will receive routine care
Study: NCT04290793

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 90mg/m\^2 d1 iv Q2W for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 90mg/m\^2 d1 iv Q2W for 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m\^2 d1 iv Q2W for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m\^2 d1 iv Q2W for 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxanes
Description: Albumin paclitaxel（125mg/m2 d1、8 iv Q3W for 4 Cycles）/Docetaxel(100mg/m2 d1 iv Q3W for 4 Cycles )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxanes
Description: Albumin paclitaxel（125mg/m2 d1、8 iv Q3W for 4 Cycles）/Docetaxel(100mg/m2 d1 iv Q3W for 4 Cycles )

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: the first cycle is a loading dose of 8 mg / kg, followed by 6 mg / kg. Iv Q3W for 1 year

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: the first cycle is a loading dose of 8 mg / kg, followed by 6 mg / kg. Iv Q3W for 1 year
Study: NCT01438801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nutropin [Somatropin (rDNA origin) for injection]
Description: Doses in the diagnostic protocol are 0.7 and 1.4 mg/m2/day, injected by subcutaneous injection at bedtime for 2 weeks, divided by washout periods of preferably 4 weeks (accepted range 4-6 weeks). An additional period of 2 weeks on 2.8 mg/m2/day (after a washout period of 4-6 weeks) will be added if the IGF-I response on either dosage is insufficient (serum IGF-I SDS \<0).
Study: NCT01371253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nintendo wii balance training

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EVA-soles
Study: NCT00405964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-mg Desloratadine
Description: 5-mg Desloratadine tablet, once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet, once daily for 12 weeks